Table 2. Clinicopathological characteristics of the patients.
|
Gender | |
| Male | 41 |
| Female |
19 |
|
Age at diagnosis, years | |
| Mean | 61, 58 |
| Range |
44–81 |
|
Site | |
| Oral cavity | 7 |
| Oropharynx | 30 |
| Hypopharynx | 9 |
| Larynx | 9 |
| Nasopharynx | 1 |
| Carcinoma of unknown primary (CUP) | 3 |
| Other |
1 |
|
Tumour size | |
| T0 | 3 |
| T1 | 1 |
| T2 | 13 |
| T3 | 11 |
| T4a | 26 |
| T4b |
6 |
|
Nodal stage | |
| N0 | 5 |
| N1 | 7 |
| N2a | 3 |
| N2b | 26 |
| N2c | 17 |
| N3 |
2 |
|
Stage (UICC) | |
| I | 0 |
| II | 1 |
| III | 7 |
| Iva | 41 |
| IVb |
7 |
|
p16 Expression | |
| No p16 expression | 29 |
| Focal p16 expression | 8 |
| Moderate diffuse p16 expression | 6 |
| High diffuse p16 expression |
17 |
|
Chemotherapy | |
| MMC/5-FU | 45 |
| Cisplatin/5-FU | 7 |
| MMC/Cetuximab | 1 |
| Other |
7 |
|
Radiotherapy | |
| Treated | 60 |
| Range of the total doses (Gy) |
66–70 |
|
Response to the primary therapy | |
| Responder | 36 |
| Non-responder |
24 |
|
Recurrence | |
| No recurrence | 43 |
| Recurrence | 13 |
Abbreviations: 5-FU=5-fluorouracil; MMC=mitomycin C; UICC=Union for International Cancer Control.